127 results about "Dpp iv inhibitors" patented technology

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula Ia or Ib:

wherein the substituents are as described herein.

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I:

wherein the substituents are as described herein.

The invention relates to thiadiazole derivatives which are shown as a formula I and have DPP-IV (dipeptidyl peptidase IV) inhibition activity, a preparation method of the thiadiazole derivatives and drug compositions of the thiadiazole derivatives, and application of the thiadiazole derivatives to treatment of diseases beneficial from DPP-IV inhibition, especially application to treatment of diabetes mellitus type 2. The thiadiazole derivatives provided by the invention have very good DPP-IV inhibition activity, have a very good in-vivo metabolic level and a very proper in-vivo half-life period and are expected to be used as proper DPP-IV inhibitor drugs.

Methods for treating diabetes by increasing the insulin secretion by administration of a GLP-1 receptor agonist and/or a DPP-IV inhibitor in combination with a proton pump inhibitor and optionally a PPAR agonist are provided.

Use of oxymethylene aryl GPR119 agonists and DPP IV inhibitors for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control are provided.

A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.

A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.

The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.

The invention provides a compound preparation containing a DPP-IV (dipeptidyl peptidase-IV) inhibitor and a type-II diabetes medicine and a preparation method thereof. According to the invention, two effective pharmaceutical ingredients are respectively prepared into a quick-release part and a slow-release part (controlled-release part) and then prepared into the compound preparation finally; the problem of combining the DPP-IV inhibitor with other diabetes medicines is solved; compliance of patients is increased; the curative effects and durations of medicines are increased maximally; the compound preparation disclosed by the invention has good effects and practical significance for treating or preventing one or more symptoms, such as type-I diabetes, type-II diabetes, hyperglycemia and impaired glucose tolerance.

The invention belongs to the field of marine organism small-molecular active peptides, and particularly relates to an anti-oxidation and DPP-IV inhibition active peptide derived from apostichopus japonicus by enzymolysis. The amino acid sequence of the anti-oxidation and DPP-IV inhibition active peptide is Ser-Arg-Pro-Gln-Tyr-Pro-Gln-Tyr-Pro-Ser. The anti-oxidation and DPP-IV inhibition active peptide is prepared by the following steps: adding water into fresh apostichopus japonicus for homogenizing, and placing the homogenate in an enzymolysis tank; performing enzymolysis with compound protease to obtain enzymatic hydrolysate; treating the enzymatic hydrolysate with a membrane separation technology to obtain a small-molecular active peptide crude product; separating the crude product through Sephadex LH-20 to obtain a small-molecular active peptide. The purity of the small-molecular active peptide as measured by adopting RP-HPLC (Reversed-Phase High Performance Liquid Chromatography)is greater than 95 percent, and the amino acid composition of the active peptide is measured by high performance liquid chromatography/mass spectrometry, so that the amino acid sequence of the small-molecular peptide is determined finally. The active small-molecular peptide derived from the apostichopus japonicus has the advantages of small molecular weight, simple separating-purifying steps, easiness in preparation, high purity and higher oxidization resistance and DPP-IV inhibition activity, has the characteristics of naturalness, safety and high efficiency, can be applied to the preventionand treatment of relevant diseases such as diabetes mellitus as an antioxidant as well as a DPP-IV inhibitor, and has a wide application prospect in the fields of foods, health care products and medicines.